DENNIS H. LANGER

Corporate Board Profile

Tech Score: 0/100

Eterna Therapeutics Inc.

Filing Date	Source Excerpt
2021-07-01	Dennis H. Langer Age: 69 Board Service · Tenure: Since May 2021 · Committees: ○ Audit (Chair) ○ Compensation (Chair) INDEPENDENT
2022-04-26	Dennis H. Langer, M.D., J.D., has served on our Board of Directors since May 2021. Dr. Langer has served as director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies, including Chairman and Chief Executive Officer of AdvanDx, Inc. from 2013 to 2014, Managing Partner of Phoenix IP Ventures, LLC from 2005 to 2010, President, North America for Dr. Reddy’s Laboratories, Inc. from 2004 to 2005, a Senior Vice President, Research and Development at GlaxoSmithKline and SmithKline Beecham from 1994 to 2004, and Chief Executive Officer of Neose Technologies, Inc. from 1991 to 1994. Previously, Dr. Langer held research and development and marketing positions at Lilly, Abbott and Searle. Dr. Langer is a Director of Myriad Genetics, Inc. (Nasdaq: MYGN) and Quoin Pharmaceuticals, Inc. (Nasdaq: QNRX), and during the past five years, Dr. Langer served on the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) and Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX). Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. Dr. Langer’s qualifications to serve on our Board of Directors include his experience in company strategy, operations, corporate development and financing as a former pharmaceutical executive and CEO of bio-pharmaceutical companies, and his management and corporate governance expertise from serving on several public company boards in the healthcare industry. The table below provides current committee membership information and the number of meetings held in 2021: Dennis Langer: Audit Committee member, Compensation Committee Chair. 2021 Director Compensation: $396,409.

Filing Date

Source Excerpt

2021-07-01

Dennis H. Langer Age: 69 Board Service · Tenure: Since May 2021 · Committees: ○ Audit (Chair) ○ Compensation (Chair) INDEPENDENT

2022-04-26

Dennis H. Langer, M.D., J.D., has served on our Board of Directors since May 2021. Dr. Langer has served as director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies, including Chairman and Chief Executive Officer of AdvanDx, Inc. from 2013 to 2014, Managing Partner of Phoenix IP Ventures, LLC from 2005 to 2010, President, North America for Dr. Reddy’s Laboratories, Inc. from 2004 to 2005, a Senior Vice President, Research and Development at GlaxoSmithKline and SmithKline Beecham from 1994 to 2004, and Chief Executive Officer of Neose Technologies, Inc. from 1991 to 1994. Previously, Dr. Langer held research and development and marketing positions at Lilly, Abbott and Searle. Dr. Langer is a Director of Myriad Genetics, Inc. (Nasdaq: MYGN) and Quoin Pharmaceuticals, Inc. (Nasdaq: QNRX), and during the past five years, Dr. Langer served on the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) and Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX). Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. Dr. Langer’s qualifications to serve on our Board of Directors include his experience in company strategy, operations, corporate development and financing as a former pharmaceutical executive and CEO of bio-pharmaceutical companies, and his management and corporate governance expertise from serving on several public company boards in the healthcare industry. The table below provides current committee membership information and the number of meetings held in 2021: Dennis Langer: Audit Committee member, Compensation Committee Chair. 2021 Director Compensation: $396,409.

SKINVISIBLE, INC.

Filing Date	Source Excerpt
2018-10-19	Dennis H. Langer, Director. Dr. Langer is a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Pernix Therapeutics Holdings, Inc., and several private health care companies. He has served as a Director of several public and private biotechnology, specialty pharmaceutical and diagnostic companies, including Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), Ception Therapeutics, Inc. (acquired by Cephalon, Inc.), Transkaryotic Therapies, Inc. (acquired by Shire plc), Pharmacopeia, Inc. (acquired by Ligand, Inc.), Cytogen Corporation (acquired by EUSA Pharma, Inc.) and Delcath Systems, Inc. He was a Managing Partner at Phoenix IP Ventures, LLC from 2005-2010. From 2004-2005, he was President, North America for Dr. Reddy's Laboratories, Inc. Dr. Langer was with GlaxoSmithKline from 1994-2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. He also served as President and CEO at Neose Technologies, Inc. from 1991-1994. Previously, Dr. Langer held R&D and marketing positions at Eli Lilly, Abbott, and Searle. Dr. Langer is a Clinical Professor in the Department of Psychiatry at Georgetown University School of Medicine. He was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health. Dr. Langer serves on the Dean's Advisory Board of Harvard Law School. He received an M.D. from Georgetown University School of Medicine, a J.D. (cum laude) from Harvard Law School, and a BA. in Biology from Columbia University.

Filing Date

Source Excerpt

2018-10-19

Dennis H. Langer, Director. Dr. Langer is a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Pernix Therapeutics Holdings, Inc., and several private health care companies. He has served as a Director of several public and private biotechnology, specialty pharmaceutical and diagnostic companies, including Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), Ception Therapeutics, Inc. (acquired by Cephalon, Inc.), Transkaryotic Therapies, Inc. (acquired by Shire plc), Pharmacopeia, Inc. (acquired by Ligand, Inc.), Cytogen Corporation (acquired by EUSA Pharma, Inc.) and Delcath Systems, Inc. He was a Managing Partner at Phoenix IP Ventures, LLC from 2005-2010. From 2004-2005, he was President, North America for Dr. Reddy's Laboratories, Inc. Dr. Langer was with GlaxoSmithKline from 1994-2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. He also served as President and CEO at Neose Technologies, Inc. from 1991-1994. Previously, Dr. Langer held R&D and marketing positions at Eli Lilly, Abbott, and Searle. Dr. Langer is a Clinical Professor in the Department of Psychiatry at Georgetown University School of Medicine. He was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health. Dr. Langer serves on the Dean's Advisory Board of Harvard Law School. He received an M.D. from Georgetown University School of Medicine, a J.D. (cum laude) from Harvard Law School, and a BA. in Biology from Columbia University.

Data sourced from SEC filings. Last updated: 2025-12-06